Search

Your search keyword '"Couselo, José Miguel"' showing total 8 results
Start Over Author "Couselo, José Miguel"
8 results on '"Couselo, José Miguel"'

1. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005

Author

Rives, Susana, Estella, Jesús, Gómez, Pedro, López-Duarte, Mónica, de Miguel, Purificación García, Verdeguer, Amparo, Moreno, Maria José, Vivanco, José Luis, Couselo, José Miguel, Fernández-Delgado, Rafael, Maldonado, Marisol, Tasso, María, López-Ibor, Blanca, Lendínez, Francisco, López-Almaraz, Ricardo, Uriz, Javier, Melo, Montserrat, Fernández-Teijeiro, Ana, Rodríguez, Isidoro, and Badell, Isabel

Published
2011
Full Text
View/download PDF

3. Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)

Author

Pérez‐Martínez, Antonio, primary, Ferreras, Cristina, additional, Pascual, Antonia, additional, Gonzalez‐Vicent, Marta, additional, Alonso, Laura, additional, Badell, Isabel, additional, Fernández Navarro, José María, additional, Regueiro, Alexandra, additional, Plaza, Mercedes, additional, Pérez Hurtado, Jose María, additional, Benito, Ana, additional, Beléndez, Cristina, additional, Couselo, José Miguel, additional, Fuster, José Luis, additional, Díaz‐Almirón, Mariana, additional, Bueno, David, additional, Mozo, Yasmina, additional, Marsal, Julia, additional, Gómez López, Alicia, additional, Sisinni, Luisa, additional, Heredia, Cristina Díaz, additional, and Díaz, Miguel Ángel, additional

Published
2019
Full Text
View/download PDF

4. Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)

Author

Pérez‐Martínez, Antonio, Ferreras, Cristina, Pascual, Antonia, Gonzalez‐Vicent, Marta, Alonso, Laura, Badell, Isabel, Fernández Navarro, José María, Regueiro, Alexandra, Plaza, Mercedes, Pérez Hurtado, Jose María, Benito, Ana, Beléndez, Cristina, Couselo, José Miguel, Fuster, José Luis, Díaz‐Almirón, Mariana, Bueno, David, Mozo, Yasmina, Marsal, Julia, Gómez López, Alicia, and Sisinni, Luisa

Published
2020
Full Text
View/download PDF

5. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH)

Author

González-Vicent, Marta, primary, Sanz, Jaime, additional, Fuster, José Luis, additional, Cid, Joan, additional, de Heredia, Cristina Díaz, additional, Morillo, Daniel, additional, Fernández, José María, additional, Pascual, Antonia, additional, Badell, Isabel, additional, Serrano, David, additional, Fox, Laura, additional, de la Serna, Javier, additional, Benito, Ana, additional, Couselo, José Miguel, additional, Molina, Blanca, additional, Díaz, Miguel Ángel, additional, and Sanz, Miguel Ángel, additional

Published
2018
Full Text
View/download PDF

6. Leucemia linfoblástica aguda T pediátrica: análisis de supervivencia y factores pronósticos en 4 protocolos consecutivos del grupo cooperativo multicéntrico SHOP

Author

Rives, Susana, primary, Estella, Jesús, additional, Camós, Mireia, additional, García-Miguel, Purificación, additional, Verdeguer, Amparo, additional, Couselo, José Miguel, additional, Tasso, María, additional, Molina, Javier, additional, Gómez, Pedro, additional, Fernández-Delgado, Rafael, additional, Navajas, Aurora, additional, and Badell, Isabel, additional

Published
2012
Full Text
View/download PDF

7. Intermediate Dose of Imatinib In Combination with Chemotherapy Followed by Allogeneic Stem Cell Transplantation (SCT) Improves Early Outcome In Childhood Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Results of the Spanish Cooperative Group SHOP/SEHOP Studies SHOP 94, SHOP 99 and SHOP 05

Author

Rives, Susana, primary, Estella, Jesús, additional, Camós, Mireia, additional, Gómez, Pedro, additional, Bureo, Encarnación, additional, de Miguel, Purificación García, additional, Verdeguer, Amparo, additional, Moreno, Maria José, additional, Urrutia, Emilia, additional, Vivanco, José Luis, additional, Couselo, José Miguel, additional, Fernández-Delgado, Rafael, additional, Maldonado, Marisol, additional, Tasso, María, additional, López-Ibor, Blanca, additional, Lendínez, Francisco, additional, de los Ángeles Vázquez, María, additional, López-Almaraz, Ricardo, additional, Uriz, Javier, additional, Melo, Montserrat, additional, Fernández-Teijeiro, Ana, additional, Rodríguez, Isidoro, additional, and Badell, Isabel, additional

Published
2010
Full Text
View/download PDF

8. [T-cell pediatric acute lymphoblastic leukemia: analysis of survival and prognostic factors in 4 consecutive protocols of the Spanish cooperative study group SHOP].

Author

Rives S, Estella J, Camós M, García-Miguel P, Verdeguer A, Couselo JM, Tasso M, Molina J, Gómez P, Fernández-Delgado R, Navajas A, and Badell I

Subjects
Adolescent, Antineoplastic Agents administration & dosage, Child, Child, Preschool, Consolidation Chemotherapy, Female, Follow-Up Studies, Humans, Induction Chemotherapy, Infant, Maintenance Chemotherapy, Male, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma mortality, Retrospective Studies, Spain, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Background and Objectives: Acute lymphoblastic leukemia (ALL) is the most frequent cancer in childhood, with cure rates of 80-85%. In T-cell ALL (15% of ALL), prognostic factors are ill defined. We aimed to describe the event-free survival (EFS) and analyze clinical prognostic factors in a series of pediatric T-ALL of 4 consecutive clinical trials., Patients and Methods: Children with T-ALL aged 1-18 years treated in 37 institutions in Spain were enrolled in 4 consecutive trials from February-1989 to November-2009., Results: A total of 218 T-ALL patients out of 1,652 pediatric ALL were evaluable during the study period (SHOP/ALL-89: 35, ALL-94: 63, ALL-99: 62, ALL-2005: 58). There were 164 boys (75%). Median age (years) was 7.8 range (1.3-18.6). Median leukocytes (10(9)/L) was 78.2, range 0.8-930. Fifteen (6.8%) children had central nervous system (CNS) involvement at diagnosis. Regarding response to induction treatment, 150 (75%) patients had less than 5% blasts on day-14 bone marrow and 199 achieved complete remission at the end of induction. Overall survival (OS) at 60 months for SHOP/ALL-89, ALL-94, ALL-99 was 48 (8), 49 (6), 70 (6) %, respectively, and at 48 months for SHOP/ALL-2005 (ongoing protocol) was 74 (8) %. Median follow-up (months) was 206, 152, 74 and 17 respectively. Analysis of prognostic factors revealed no statistical differences regarding sex or age. Leukocyte count over 200×10(9)/l (P=.024), CNS infiltration at diagnosis (P<.006) and treatment response had prognostic significance (end-induction complete remission) (P=.0000), day 14-bone marrow (P=.005)., Conclusions: Results for the SHOP/ALL-89 and ALL-94 protocols were inferior to other contemporary protocols but there has been an improvement in survival in the 2 last trials. In line with other T-ALL series, response to treatment had the strongest prognostic impact., (Copyright © 2011 Elsevier España, S.L. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results